Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines.

Link BK, Brooks J, Wright K, Pan X, Voelker M, Chrischilles E.

Leuk Lymphoma. 2011 Jun;52(6):994-1002. doi: 10.3109/10428194.2011.557167. Epub 2011 Feb 21.

2.

Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.

Griffiths RI, Gleeson ML, Mikhael J, Dreyling MH, Danese MD.

Cancer. 2012 Dec 15;118(24):6079-88. doi: 10.1002/cncr.27638. Epub 2012 May 30.

3.

Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.

Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S.

Oncologist. 2014 Dec;19(12):1249-57. doi: 10.1634/theoncologist.2014-0113. Epub 2014 Oct 23.

4.

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, Véra P, Copie-Bergman C, Rahmouni A, Tilly H, Meignan M, Haioun C.

J Clin Oncol. 2012 Jan 10;30(2):184-90. doi: 10.1200/JCO.2011.38.2648. Epub 2011 Dec 12.

5.

Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile.

Tien YY, Link BK, Brooks JM, Wright K, Chrischilles E.

Leuk Lymphoma. 2015 Jan;56(1):65-71. doi: 10.3109/10428194.2014.903589. Epub 2014 Apr 22.

6.

The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.

Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, Martinelli G, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M.

Am J Hematol. 2015 Jan;90(1):56-61. doi: 10.1002/ajh.23872. Epub 2014 Nov 19.

7.

Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.

Olszewski AJ, Winer ES, Castillo JJ.

Leuk Res. 2014 Aug;38(8):866-73. doi: 10.1016/j.leukres.2014.04.009. Epub 2014 May 1.

PMID:
24837081
8.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
9.

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.

Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.

Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.

PMID:
21874232
10.

Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.

Shah BK, Bista A, Shafii B.

Anticancer Res. 2014 Sep;34(9):5117-20.

PMID:
25202101
11.

A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.

Niitsu N, Tamaru J, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Okamoto M.

Ann Hematol. 2011 Feb;90(2):185-92. doi: 10.1007/s00277-010-1060-8. Epub 2010 Sep 1.

PMID:
20809421
12.

Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.

Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M.

J Clin Oncol. 2014 Oct 10;32(29):3242-8. doi: 10.1200/JCO.2013.53.4537. Epub 2014 Aug 18.

13.

Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma.

Conrad AL, Gundrum JD, McHugh VL, Go RS.

J Oncol Pract. 2012 Nov;8(6):336-40. doi: 10.1200/JOP.2012.000682. Epub 2012 Sep 18.

14.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

15.

Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.

Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, Polo M, López J, Conde E, Jarque I, Alonso N, Ramírez MJ, Fernández P, Sayas MJ, Requena MJ, Salar A, González JD, González-Barca E, Arranz R, Caballero D, Martín A.

Br J Haematol. 2014 Mar;164(5):668-74. doi: 10.1111/bjh.12676. Epub 2013 Nov 26.

PMID:
24274082
16.

A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.

Mian M, Augustin F, Kocher F, Gunsilius E, Willenbacher W, Zabernigg A, Zangerl G, Oexle H, Schreieck S, Schnallinger M, Fiegl M.

Anticancer Res. 2014 May;34(5):2559-64.

PMID:
24778077
17.
18.

Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database.

Olszewski AJ, Castillo JJ.

Ann Oncol. 2013 May;24(5):1352-9. doi: 10.1093/annonc/mds644. Epub 2013 Jan 24.

19.

Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.

Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.

Am J Hematol. 2013 May;88(5):400-5. doi: 10.1002/ajh.23423. Epub 2013 Mar 19.

20.

Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.

Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K, Krahn M, Hodgson DC.

Br J Haematol. 2012 Aug;158(4):481-8. doi: 10.1111/j.1365-2141.2012.09177.x. Epub 2012 Jun 5.

PMID:
22671571
Items per page

Supplemental Content

Write to the Help Desk